Rodríguez MA, Ascencio HL, Altamirano GJT

Language: Spanish
References: 24
Page: 426-430
PDF size: 56.82 Kb.

ABSTRACT

Background: There is an evident relation between the onset and exacerbation of the symptoms of irritable bowel disease and the psychogenic status. Many of these patients suffer from neurosis, mainly anxiety and depression; which can influence the response to treatment.
Objective: To assess the clinical response to pharmacological treatment with pinaverium bromide in a group of patients with diagnosis of irritable bowel syndrome and several degrees of neurosis.
Patients and methods: We conducted a prospective, comparative and longitudinal trial in patients with irritable bowel disease and various degrees of neurosis on treatment with pinaverium bromide.
Results: 36 patients completed the study, 34 women and 2 men; the medium age was 42 years. All of them with different degrees of neurosis: 6 cases with mild depression, 19 moderate and 11 with severe disease. The efficacy of treatment in mild disease (n=3) was: poor in 1 case, regular in 2 cases and good in 3; with moderate depression (n=19) the response was: poor in 7 cases, moderate in 6, and good in 6; the severe depression (n=11) groups shows 3 cases with poor response, regular response in 5 cases, and good in 3 patients (p=0.74). Otherwise patients with mild anxiety (n=3) the response to treatment was: moderate in 1 case and good in 2 cases. In moderate anxiety (n=12), 5 had poor response to treatment, 4 with moderate response and good in 3 cases. In severe anxiety (n=21), 6 had poor response to treatment, 8 with moderate response and 7 with good response (p=0.26).
Conclusion: Results show no relationship between the degree of severity of anxiety/depression and the outcome after therapy with pinaverium bromide in the irritable bowel disease patients.

REFERENCES

1. Drossman LA, Li Z, Andruzzi E, et al. US householders survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-80.

2. Mitehell CM, Drossman DA. Survell of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:128-84.

3. O’Keefe EA, Talley NJ, Zinsmeister AR, et al. Bowel disorders impair fuctional status and quality of life in the elderly: a population based study. Am J Gastroenterol 1995:50:184-9.

4. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, RomeII. A multinational consensus document on fuctional gastroentestinal disorders. Gut 1999;45(Suppl 2):111-8.

5. Whitehead WE, Holtkotter B, Enck P, Holmes K, Anthony J. Tolerance for rectosig moid distention in irritable bowel syndrome. Gastroenterol 1990;98:1187-92.

6. Gershon MD. Review article: roles played by 5-hidroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999;13:15-30.

7. Whitehead WE, Bosmajian L, Zonderman A, et al. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988;95:709-14.

8. Welch GW, Hillman LC, Pomare EW. Psychoneurotic symptomatology in the irritable bowel syndrome: a study of reporters and non reporters. Br Med J 1985;291:1382-4.

9. Drossman DA, Mckee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. Gastroenterology 1988;95:701-8.

10. Blauchard EB. The role of anxiety and depression in the irritable bowel syndrome. Behav Res Ther 1990;28:401-95.

11. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia and psychosocial factors. Am J Gastroenterol 2001;96:1340-9.

12. Mayer EA, Naliboff B, Lee D, Munakata J, Chang I. Gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999;13(Suppl 2):65-69.

13. Gear RW, Miaskowki C, Gordon N, Paul S, Heller P, Levin K. Opioids produce significantly greater analgesia in women than in men. Nature Med 1995;2:1248-50.

14. Jackson NA, Houghton LA, Whowell PJ. The menstrual cycle affects rectal visceral sensity in patients with irritable bowel syndrome but not in healthy volunteers. Gastroenterol 1997;112:A1132.

15. Drossman DA, Liz MA, Loserman J, et al. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996;999:1007.

16. Talley NJ, Fett SL, Zinsmeister AR, et al. Gastrointestinal tract symptoms and self-report abuse: a population based study. Gastroenterology 1994;107:1040-9.

17. Ferom O, Dessy C, Christen M, Godfraind T. Importance of the L-type calcium channel pathway in the process of internal calcium stores refilling in intestinal smooth muscle (abstr). Gastroenterology 1995;108:A598.

18. Chrsiten MO. Pinaverium bromide: a calcium antagonist with selectivity for the gastrointestinal tract. Today’s Therapeutic Trend 1995;13(2):47-62.

19. Farraway L, Malysz J, Christen M, Huizinga J. Action of pinaverium bromide on action potential generation in circular and longitudinal colonic smooth muscle (abstr). Gastroenterology 1993;104A:506

20. Poynard T, Naveau S, Mory B, Chaput J. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499-510.

21. Awad R, Cordova VH, Dibildox M, et al. Reduction of postprandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome. Acta Gastroenterol Latinoam 1997;27(4):247-51.

22. Fioramenti J, Christen M, Dupre I, Bueno L. Action of the calcium channel blocker pinaverium bromide on the CCK-mediated colonic motor response to a meal in rats (abstr). Gastroenterology 1995;108A:598.

23. Jule Y, Christen M. Pinaverium bromide inhibition of substance-P induced desen-dind activation in the guinea-pig distal colon (abstr). Gastroenterology 1995;108A:624.

24. Locke GR, Weaver AL, Melton LJ, Talley NJ. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested cases control study. Am J Gastroenterol 2004;99:350-7.